Gratacós-Ginés, J, Alvarado-Tapias, E, Martí-Aguado, D, López-Pelayo, H, Bataller, R, Pose, E. Diagnosis and Management of Early Stages of ALD. SEMINARS IN LIVER DISEASE. 2025; 45(02)DOI:10.1055/a-2541-2892. PMID:39965759. IF:3.700(Q2/3D).

Zhang, YL, Tedeschi, SK, Abhishek, A, Hensey, O, Grossberg, D, Cai, K, Shea, B, Singh, JA, Christensen, R, Serban, T, Cipolletta, E, Parperis, K, Diaz-Torne, C, Mccarthy, GM, Becce, F, Gheita, TA, Sirotti, S, Christiansen, SN, Coronel, L, Stamp, LK, Abdel-Fattah, YH, Pascart, T, Filippou, G, Hong, LE, Fitzgerald, J, Dalbeth, N. Core domain set for chronic and/or recurrent manifestations of calcium pyrophosphate deposition disease: OMERACT delphi survey to establish consensus. SEMINARS IN ARTHRITIS AND RHEUMATISM. 2025; 72DOI:10.1016/j.semarthrit.2025.152669. PMID:40086154. IF:4.400(Q1/1D).

Martinez-Molina, C, Park, HS, Díaz-Torné, C, Vidal, S, Corominas, H. FACTORS ASSOCIATED WITH ACHIEVING REMISSION OR LOW DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING JANUS KINASE INHIBITOR TREATMENT. ANNALS OF THE RHEUMATIC DISEASES. 2025; 84DOI:10.1136/annrheumdis-2025-eular.B3700. PMID:. IF:20.600(Q1/1D).

Azuaga, AB, Cuervo, A, Reina, D, Estrada, P, Soria, LM, Aparicio, M, Moreno, M, Arevalo, M, Laiz, A, Moya, P, Alascio, L, Riera, J, Scher, JU, Crespillo, JDDC, Ramirez, J. CLINICAL AND ULTRASOUND FEATURES OF A COHORT OF PSO PATIENTS WITHOUT MUSCULOSKELETAL SYMPTOMS: A PROSPECTIVE AND MULTICENTER STUDY. ANNALS OF THE RHEUMATIC DISEASES. 2025; 84DOI:10.1136/annrheumdis-2025-eular.B1990. PMID:. IF:20.600(Q1/1D).

Retuerto-Guerrero, M, Morales, CM, Santos, CS, Herránz, LS, Juan, J, Castellví, I, Alvarez, ED. EVALUATION OF THE NEW CRITERIA FOR PROGRESSIVE PULMONARY FIBROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS. ANNALS OF THE RHEUMATIC DISEASES. 2025; 84DOI:10.1136/annrheumdis-2025-eular.B1643. PMID:. IF:20.600(Q1/1D).

Retuerto-Guerrero, M, Morales, CM, Santos, CS, Herránz, LS, Juan, J, Castellvi, I, Alvarez, ED. COMPARATIVE ANALYSIS OF PROGRESSIVE PULMONARY FIBROSIS CRITERIA IN SYSTEMIC SCLEROSIS PATIENTS. ANNALS OF THE RHEUMATIC DISEASES. 2025; 84DOI:10.1136/annrheumdis-2025-eular.B1597. PMID:. IF:20.600(Q1/1D).

Valera-Ribera, C, Alegre-Sancho, JJ, Castellvi, I, Ibanez, M, Garcia, FJN. DISTINCTIVE CLINICAL TRAITS OF ANTICENTROMERE ANTIBODY-POSITIVE SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: A MULTICENTER RETROSPECTIVE STUDY. ANNALS OF THE RHEUMATIC DISEASES. 2025; 84DOI:10.1136/annrheumdis-2025-eular.B3437. PMID:. IF:20.600(Q1/1D).

Paños, HB, Saborit, MC, Lasanta, MAL, Lizarzaburu, MS, Ruiz-Esquide, V, Vilaseca, DR, Nack, A, Perez-Garcia, C, Bernardez, J, Guillen, AG, Aguilar, JR, Cuervo, A, Roc, MV, Gomez, CG, Mínguez, S, Novell, RM, Estrada, P, Martinez-Morillo, M, Grau, CP, Busquets-Perez, N, Park, HS, Gómez-Puerta, JA, Pérez, SH, Palau, NM, Sanmarti, R, Mateo, L, Diaz-Torne, C, Corominas, H, Alarcon, GS. UNDERSTANDING THE IMPACT OF EMA/PRAC SAFETY RECOMMENDATIONS ON THE REAL-WORLD USE OF JAK INHIBITORS IN RA. ANNALS OF THE RHEUMATIC DISEASES. 2025; 84DOI:10.1136/annrheumdis-2025-eular.B3117. PMID:. IF:20.600(Q1/1D).